VivoSim Labs, Inc. (VIVS)
Nasdaq: VIVS · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2010
Who owns VivoSim Labs, Inc.
As filed with the SECHolders of 5% or more
1
Esousa Group Holdings LLC holds 9.9% of Common Stock, as its SCHEDULE 13G/A filed Aug 17, 2026 says.
Directors and officers
7
report now, of 29 people on the record since 2012. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Esousa Group Holdings LLC
SCHEDULE 13G/A · filed Aug 17, 2026 · Common Stock · 9.9% in Apr 6, 2026
Armistice Capital, LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, $0.001 par value · reported falling below 5%, from 9.99% in Feb 14, 2025
What VIVS reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Metacrine's FXR Program
A company bought · asset acquisition · owns, named in the 10-K filed Jul 14, 2026
2 subsidiaries in 1 country, from the list filed with the 10-K filed Jul 14, 2026.
Insider tradesForm 4
1sales
1purchases
0sales on a scheduled plan
1people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 29 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Lialin Tony Serge | Chief Commercial Officer | 0 | $0 | 0 | 1 | $0 |
| Gobel David | director | 1 | $0 | 0 | 0 | $0 |